首页> 外文期刊>Open Veterinary Journal >Therapeutic equivalence of ivermectin 1% and two novel formulations combined of ivermectin 1% fluazuron 12.5% for the control of Rhipicephalus (Boophilus) microplus in beef cattle from Uruguay
【24h】

Therapeutic equivalence of ivermectin 1% and two novel formulations combined of ivermectin 1% fluazuron 12.5% for the control of Rhipicephalus (Boophilus) microplus in beef cattle from Uruguay

机译:Ivermectin的治疗当量1%和两种新制剂联合Ivermectin 1%麦芽糖12.5%的12.5%用于乌拉圭牛肉中的Rapicephalus(Boophilus)Microplus的控制

获取原文
           

摘要

Background: Novel combinations of ivermectin (IVM) and fluazuron (FLU) are presented as an alternative for the control of ticks in cattle. Applying a combination of drugs with the aim to affect different stages of the parasite’s life cycle is established as a potential measure to achieve the control of ticks in cattle. Aim: To determine the therapeutic equivalence between two novel formulations of IVM 1% combined with FLU 12.5% tested on bovines naturally infested with Rhipicephalus (Boophilus) microplus. Methods: Forty adult beef cattle were randomized into four groups (n = 10): IVM [1% (0.2 mg/kg)], combinations groups A and B [IVM 1% (0.2 mg/kg) FLU 12.5% (2.5 mg/kg), each], and control [untreated]). On days 14, 27, and 49 after administration, the presence of ticks was ranked as null, low, medium, and high; a cumulative link model was adjusted to evaluate treatment response. Results: Although all groups had some animals with the presence of ticks until day 27, on day 14 IVM [odds ratios (OR) 0.013, CI95%: 0.001–0.014, p 0.01], A (OR 0.01, CI95%: 0.00–0.07, p 0.01) and B (OR 0.01, CI95%: 0.00–0.148, p 0.01) groups were different when compared to the control group, unlike on day 27 where only groups A (OR 0.02, CI95%: 0.00–0.17, p 0.01) and B (OR 0.06, CI95%: 0.00–0.46, p 0.01) remained different from the control group. On day 49 post-administration, IVM and B did not differ from the control group, with 0.95 probability (CI95% 0.92–1.02) of high parasite burden. At day 49 post-administration, group A was the only group free of ticks (OR 0.01, CI95%: 0.00–0.13, p 0.01). Conclusions: Pharmacotechnical differences in combined formulations should be considered in therapeutic equivalence studies.
机译:背景:伊维菌素(IVM)和麦芽酮(流感)的新组合作为控制牛中蜱的替代方案。将药物组合应用于影响寄生虫生命周期的不同阶段的潜在措施,以实现牛中蜱的控制。目的:确定两种新型IVM配方之间的治疗当量,与流感相结合的12.5%在与Rapicephalus(Boophilus)Microplus自然侵染的牛对其进行测试。方法:将四十成成牛肉牛随机分为四组(n = 10):IVM [1%(0.2mg / kg)],组合组A和B [IVM 1%(0.2mg / kg)流感12.5%(2.5毫克/ kg),每个]和控制[未经处理])。在给药后的第14,27和49天,蜱的存在被排名为零,低,培养基和高;调整累积链路模型以评估治疗响应。结果:虽然所有群体都有一些动物,直到第27天,在第27天,在第14天,在第14天(OVDS比率(或)0.013,CI95%:0.001-0.014,P& 0.01](或0.01,C 195%:0.00-0.07,P& 0.01)和B(或0.01,C 195%:0.00-0.148,P <0.01,P <0.01)组不同,与对照组不同,不同于第27天,其中仅组(或0.02,CI95%:0.00-0.17,p& 0.01)和B(或0.06,C 195%:0.00-0.46,P <0.01)仍然不同于对照组。在第49天施用后,IVM和B与对照组没有不同,寄生术负担的0.95个概率(CI95%0.92-1.02)。在第49天颁发后,A组是唯一的液体,无蜱(或0.01,CI95%:0.00-0.13,P& 0.01)。结论:在治疗当量研究中应考虑组合配方中的药物技术差异。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号